Results 111 to 120 of about 8,561,878 (291)

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Development of Small Entrepreneurship in the Republic of Croatia

open access: yesEkonomski Vjesnik, 2013
Entrepreneurship is a driving force of any economy and as such, the foundation of a country’s success. Whether we speak of small, medium or large enterprises, each of them has responsibility assumed by taking on a risk of starting a new business, because
Marijan Rajsman   +2 more
doaj  

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

BENEFITS STREET – WHO BENEFITS?

open access: yes, 2014
Who would have thought that the company behind the cuddly <em> Great British Bake Off </em> format would be embroiled in one of the biggest documentary ethics blow-ups of recent years? Love Productions is indeed behind both <em> Bake Off </em> and <em> Benefits Street </em> , a five-part Channel 4 series that has “
openaire   +1 more source

Who Benefits from Economic Development? Reply [PDF]

open access: yes, 1980
[Excerpt] Before the appearance of my 1977 paper in this Review, it was widely thought that the income distribution worsened during the economic growth which took place in Brazil during the 1960\u27s.
Fields, Gary S
core   +2 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

An analysis of design reuse benefits [PDF]

open access: yes, 1998
Although the concept of design reuse is accepted as a valid approach to design, little attempt has been made to formalise the elements that constitutes design reuse. The few approaches formalising design reuse, e.g.
Duffy, A.H.B., Ferns, A. F.
core  

Convergent-Beam EMCD: Benefits, Pitfalls, and Applications

open access: yes, 2017
Energy-loss magnetic chiral dichroism (EMCD) is a versatile method for studying magnetic properties on the nanoscale. However, the classical EMCD technique is notorious for its low signal to noise ratio (SNR). Here, we study the theoretical possibilities
Löffler   +5 more
core   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

open access: yesMolecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy